SCHEMBL30906820

SCHEMBL30906820

Cc1sc(-c2nc(N[C@H]3CCN(S(=O)(=O)c4cn(C)cn4)C[C@H]3C)ncc2C(F)(F)F)cc1C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 11/20 0.49
▸ CCNE1 P24864 9/20 0.49
▸ CDK4 P11802 7/20 0.49
▸ CCND1 P24385 7/20 0.49
▸ CCND3 P30281 7/20 0.49
▸ CDK6 Q00534 7/20 0.49
▸ CDK1 P06493 7/20 0.49
▸ CCNB1 P14635 7/20 0.49
▸ CCNT1 O60563 3/20 0.49
▸ CDK7 P50613 3/20 0.49
▸ CDK9 P50750 3/20 0.49
▸ CCNH P51946 3/20 0.49
▸ MNAT1 P51948 3/20 0.49
▸ SLC6A9 P48067 4/20 0.39
▸ CCNA2 P20248 2/20 0.36
▸ CCNA1 P78396 2/20 0.36
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27213173 1.00 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906796 0.93 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213196 0.93 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213243 0.93 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906805 0.93 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213227 0.90 CDK2 (0.38) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906832 0.90 CDK2 (0.38) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906873 0.88 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL27213200 0.88 CDK2 (0.49) CDK2CCNE1CDK4CCND1CCND3
SCHEMBL30906831 0.88 CCND3 (0.47) CDK2CCNE1CDK4CCND1CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO claimed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed
Send feedback